Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives $31.67 Consensus Target Price from Analysts
Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average […]
More Stories
Oshkosh Co. (NYSE:OSK) Receives $125.79 Consensus PT from Analysts
Shares of Oshkosh Co. (NYSE:OSK – Get Free Report) have been given an average rating of “Hold” by the fourteen...
Redeia Corporación (OTCMKTS:RDEIY) versus Barratt Developments (OTCMKTS:BTDPY) Head-To-Head Review
Barratt Developments (OTCMKTS:BTDPY – Get Free Report) and Redeia Corporación (OTCMKTS:RDEIY – Get Free Report) are both finance companies, but...
Analyzing Lithia Motors (NYSE:LAD) & D’Ieteren Group (OTCMKTS:SIEVF)
Lithia Motors (NYSE:LAD – Get Free Report) and D’Ieteren Group (OTCMKTS:SIEVF – Get Free Report) are both retail/wholesale companies, but...
Short Interest in T Stamp Inc. (NASDAQ:IDAI) Increases By 57.5%
T Stamp Inc. (NASDAQ:IDAI – Get Free Report) was the recipient of a large growth in short interest in the...
Short Interest in InMed Pharmaceuticals Inc. (NASDAQ:INM) Expands By 55.3%
InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) was the recipient of a large increase in short interest during the...
Barclays Increases Cintas (NASDAQ:CTAS) Price Target to $245.00
Cintas (NASDAQ:CTAS – Get Free Report) had its target price upped by Barclays from $210.00 to $245.00 in a research...